Pharvaris reports Phase 2 CHAPTER-1 extension data showing long-term safety, attack-rate drop for deucrictibant in HAE

• Pharvaris outlined new Phase 3 and Phase 2 data for oral deucrictibant at the Bradykinin Symposium on Sept. 3-4, 2026.
• Phase 3 RAPIDe-3 analyses showed faster patient-reported improvement and earlier stabilization of hereditary angioedema attacks versus placebo.
• Phase 2 CHAPTER-1 open-label extension results indicated sustained attack prevention with long-term dosing, with favorable tolerability over extended follow-up.
• An integrated clinical review reported no meaningful cardiovascular safety concerns across the deucrictibant program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030650PRIMZONEFULLFEED9820663) on September 03, 2026, and is solely responsible for the information contained therein.